Of mice and men: innate immunity in pneumococcal pneumonia

International Journal of Antimicrobial Agents

Volumn 35, Issue 2, 2010, Pages 107-113

  Calbo, Esther ^a,b   Garau, Javier ^a  

^a HOSPITAL MÚTUA DE TERRASSA   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Cytokines; Inflammatory response; Innate immune system; Pneumonia; Streptococcus pneumoniae

Indexed keywords

CEFTRIAXONE; CYTOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 6; LEVOFLOXACIN; PATTERN RECOGNITION RECEPTOR; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA;

BACTERIAL GROWTH; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG MECHANISM; GENE ACTIVATION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; HOST RESISTANCE; HUMAN; HUMAN VERSUS ANIMAL COMPARISON; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOSTIMULATION; INFECTION RISK; INFECTION SENSITIVITY; INNATE IMMUNITY; MACROPHAGE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN SYNTHESIS INHIBITION; SHORT SURVEY; SIGNAL TRANSDUCTION; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE;

ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; IMMUNITY, INNATE; INFLAMMATION MEDIATORS; LUNG; MALE; MICE; PNEUMONIA, PNEUMOCOCCAL; SIGNAL TRANSDUCTION; STREPTOCOCCUS PNEUMONIAE; TOLL-LIKE RECEPTORS;

EID: 72449125281     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2009.10.002     Document Type: Short Survey

References (72)

1. Brandenburg J.A., Marrie T.J., Coley C.M., Singer D.E., Obrosky D.S., Kapoor W.N., et al. Clinical presentation, processes and outcomes of care for patients with pneumococcal pneumonia. J Gen Intern Med 15 (2000) 638-646
2. Ortqvist A., Grepe A., Julander I., and Kalin M. Bacteremic pneumococcal pneumonia in Sweden: clinical course and outcome and comparison with non-bacteremic pneumococcal and mycoplasmal pneumonias. Scand J Infect Dis 20 (1988) 163-171
3. Afessa B., Greaves W.L., and Frederick W.R. Pneumococcal bacteremia in adults: a 14-year experience in an inner-city university hospital. Clin Infect Dis 21 (1995) 345-351
4. Austrian R., and Gold J. Pneumococcal bacteremia with especial reference to bacteremic pneumococcal pneumonia. Ann Intern Med 60 (1964) 759-776
5. Hippenstiel S., Opitz B., Schmeck B., and Suttorp N. Lung epithelium as a sentinel and effector system in pneumonia-molecular mechanisms of pathogen recognition and signal transduction. Respir Res 7 (2006) 97
6. Akira S., Uematsu S., and Takeuchi O. Pathogen recognition and innate immunity. Cell 124 (2006) 783-801
7. Yoshimura A., Lien E., Ingalls R.R., Tuomanen E., Dziarski R., and Golenbock D. Cutting edge: recognition of Gram-positive bacterial cell wall components by the innate immune system occurs via Toll-like receptor 2. J Immunol 163 (1999) 1-5
8. Malley R., Henneke P., Morse S.C., Cieslewicz M.J., Lipsitch M., Thompson C.M., et al. Recognition of pneumolysin by Toll-like receptor 4 confers resistance to pneumococcal infection. Proc Natl Acad Sci USA 100 (2003) 1966-1971
9. Knapp S., Wieland C.W., van't Veer C., Takeuchi O., Akira S., Florquin S., et al. Toll-like receptor 2 plays a role in the early inflammatory response to murine pneumococcal pneumonia but does not contribute to antibacterial defense. J Immunol 172 (2004) 3132-3138
10. Paterson G.D., and Mitchell T.J. Innate immunity and the pneumococcus. Microbiology 152 (2006) 285-293
11. Khor C.C., Chapman S.J., Vannberg F.O., Dunne A., Murphy C., Ling E.Y., et al. A Mal functional variant is associated with protection against invasive pneumococcal disease, bacteremia, malaria and tuberculosis. Nat Genet 39 (2007) 523-528
12. Ku C.L., von Bernuth H., Picard C., Zhang S.Y., Chang H.H., Yang K., et al. Selective predisposition to bacterial infections in IRAK-4-deficient children: IRAK-4-dependent TLRs are otherwise redundant in protective immunity. J Exp Med 204 (2007) 2407-2422
13. Mizgerd J.P. Acute lower respiratory tract infection. N Engl J Med 358 (2008) 716-727
14. Tergaonkar V., Correa R.G., Ikawa M., and Verma I.M. Distinct roles of IκB proteins in regulating constitutive NF-κB activity. Nat Cell Biol 7 (2005) 921-923
15. Chapman S.J., Khor C.C., Vannberg F.O., Frodsham A., Walley A., Maskell N.A., et al. IκB genetic polymorphisms and invasive pneumococcal disease. Am J Respir Crit Care Med 176 (2007) 181-187
16. Schmeck B., Huber S., Moog K., Zahlten J., Hocke A.C., Opitz B., et al. Pneumococci induced TLR- and Rac1-dependent NF-κB-recruitment to the IL-8 promoter in lung epithelial cells. Am J Physiol Lung Cell Mol Physiol 290 (2006) L730-L737
17. Quinton L.J., Jones M.R., Simms B.T., Kogan M.S., Robson B.E., Skerrett S.J., et al. Functions and regulation of NF-κB RelA during pneumococcal pneumonia. J Immunol 178 (2007) 1896-1903
18. Alcamo E., Mizgerd J.P., Horwitz B.H., Bronson R., Beg A.A., Scott M., et al. Targeted mutation of TNF receptor I rescues the RelA-deficient mouse and reveals a critical role for NF-κB in leukocyte recruitment. J Immunol 167 (2001) 1592-1600
19. Mizgerd J.P., Lupa M.M., Kogan M.S., Warren H.B., Kobzik L., and Topulos G.P. Nuclear factor-κB p50 limits inflammation and prevents lung injury during Escherichia coli pneumonia. Am J Respir Crit Care Med 168 (2003) 810-817
20. Li Q., and Verma I.M. NF-κB regulation in the immune system. Nat Rev Immunol 2 (2002) 725-734 [Erratum in: Nat Rev Immunol 2002;2:975]
21. Jones M.R., Simms B.T., Lupa M.M., Kogan M.S., and Mizgerd J.P. Lung NF-κB activation and neutrophil recruitment require IL-1 and TNF receptor signaling during pneumococcal pneumonia. J Immunol 175 (2005) 7530-7535
22. Takashima K., Tateda K., Matsumoto T., Iizawa Y., Nakao M., and Yamaguchi K. Role of tumor necrosis factor alpha in pathogenesis of pneumococcal pneumonia in mice. Infect Immun 65 (1997) 257-260
23. Colombel J.F., Loftus Jr. E.V., Tremaine W.J., Egan L.J., Harmsen W.S., Schleck C.D., et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology 126 (2004) 19-31
24. Baghai M., Osmon D.R., Wolk D.M., Wold L.E., Haidukewych G.J., and Matteson E.L. Fatal sepsis in a patient with rheumatoid arthritis treated with etanercept. Mayo Clin Proc 76 (2001) 653-656
25. Wright T.W., Pryhuber G.S., Chess P.R., Wang Z., Notter R.H., and Gigliotti F. TNF receptor signaling contributes to chemokine secretion, inflammation, and respiratory deficits during Pneumocystis pneumonia. J Immunol 172 (2004) 2511-2521
26. Hildebrandt G.C., Olkiewicz K.M., Corrion L.A., Chang Y., Clouthier S.G., Liu C., et al. Donor-derived TNF-α regulates pulmonary chemokine expression and the development of idiopathic pneumonia syndrome after allogeneic bone marrow transplantation. Blood 104 (2004) 586-593
27. Tracey K.J., Fong Y., Hesse D.G., Manogue K.R., Lee A.T., Kuo G.C., et al. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 330 (1987) 662-664
28. Waterer G.W., Quasney M.W., Cantor R.M., and Wunderink R.G. Septic shock and respiratory failure in community-acquired pneumonia have different TNF polymorphism associations. Am J Respir Crit Care Med 163 (2001) 1599-1604
29. Wunderink R.G., Waterer G.W., Cantor R.M., and Quasney M.W. Tumor necrosis factor gene polymorphisms and the variable presentation and outcome of community-acquired pneumonia. Chest 121 3 Suppl. (2002) 87S
30. Cundell D.R., Gerard N.P., Gerard C., Idanpaan-Heikkila I., and Tuomanen E.I. Streptococcus pneumoniae anchor to activated human cells by the receptor for platelet-activation factor. Nature 377 (1995) 435-438
31. Underhill D.M., and Ozinsky A. Phagocytosis of microbes: complexity in action. Annu Rev Immunol 20 (2002) 825-852
32. Kirby A.C., Raynes J.G., and Kaye P.M. The role played by tumor necrosis factor during localized and systemic infection with Streptococcus pneumoniae. J Infect Dis 191 (2005) 1538-1547
33. Knapp S., Leemans J.C., Florquin S., Branger J., Maris N.A., Pater J., et al. Alveolar macrophages have a protective antiinflammatory role during murine pneumococcal pneumonia. Am J Respir Crit Care Med 167 (2003) 171-179
34. Marriott H.M., Hellewell P.G., Cross S.S., Ince P.G., Whyte M.K., and Dockrell D.H. Decreased alveolar macrophage apoptosis is associated with increased pulmonary inflammation in a murine model of pneumococcal pneumonia. J Immunol 177 (2006) 6480-6488
35. Kolling U.K., Hansen F., Braun J., Rink L., Katus H.A., and Dalhoff K. Leucocyte response and anti-inflammatory cytokines in community acquired pneumonia. Thorax 56 (2001) 121-125
36. Lawrence E., Van Eeden S., English D., and Hogg J.C. Polymorphonuclear leukocyte (PMN) migration in streptococcal pneumonia: comparison of older PMN with those recently released from the marrow. Am J Respir Cell Mol Biol 14 (1996) 217-224
37. Cohen M.S. Molecular events in the activation of human neutrophils for microbial killing. Clin Infect Dis 18 Suppl. 2 (1994) S170-S179
38. Biffl W.L., Moore E.E., Moore F.A., and Barnett Jr. C.C. Interleukin-6 delays neutrophil apoptosis via a mechanism involving platelet-activating factor. J Trauma 40 (1996) 575-578 [Discussion 578-9]
39. Ortqvist A., Hedlund J., Wretlind B., Carlström A., and Kalin M. Diagnostic and prognostic value of interleukin-6 and C-reactive protein in community-acquired pneumonia. Scand J Infect Dis 27 (1995) 457-462
40. Barton B.E. IL-6: insights into novel biological activities. Clin Immunol Immunopathol 85 (1997) 16-20
41. Schaaf B., Rupp J., Müller-Steinhardt M., Kruse J., Boehmke F., Maass M., et al. The interleukin-6 -174 promoter polymorphism is associated with extrapulmonary bacterial dissemination in Streptococcus pneumoniae infection. Cytokine 31 (2005) 324-328
42. Bogdan C., Vodovotz Y., and Nathan C. Macrophage deactivation by interleukin 10. J Exp Med 174 (1991) 1549-1555
43. Latifi S.Q., O'Riordan M.A., and Levine A.D. Interleukin-10 controls the onset of irreversible septic shock. Infect Immun 70 (2002) 4441-4446
44. van der Poll T., de Waal Malefyt R., Coyle S.M., and Lowry S.F. Antiinflammatory cytokine responses during clinical sepsis and experimental endotoxemia: sequential measurements of plasma soluble interleukin (IL)-1 receptor type II, IL-10, and IL-13. J Infect Dis 175 (1997) 118-122
45. Gallagher P.M., Lowe G., Fitzgerald T., Bella A., Greene C.M., McElvaney N.G., et al. Association of IL-10 polymorphism with severity of illness in community acquired pneumonia. Thorax 58 (2003) 154-156
46. Schaaf B., Boehmke F., Esnaashari H., Seitzer U., Kothe H., Maass M., et al. Pneumococcal septic shock is associated with the interleukin-10-1082 gene promoter polymorphism. Am J Respir Crit Care Med 168 (2003) 476-480
47. Kuhlman M., Joiner K., and Ezekowitz R.A. The human mannose-binding protein functions as an opsonin. J Exp Med 169 (1989) 1733-1745
48. Kaplan M.H., and Volanakis J.E. Interaction of C-reactive protein complexes with the complement system. I. Consumption of human complement associated with the reaction of C-reactive protein with pneumococcal C-polysaccharide and with the choline phosphatides, lecithin and sphingomyelin. J Immunol 112 (1974) 2135-2147
49. Horowitz J., Volanakis J.E., and Briles D.E. Blood clearance of Streptococcus pneumoniae by C-reactive protein. J Immunol 138 (1987) 2598-2603
50. Roy S., Hill A.V., Knox K., Griffiths D., and Crook D. Research pointers: association of common genetic variants with susceptibility to invasive pneumococcal disease. BMJ 324 (2002) 1369
51. Roy S., Knox K., Segal S., Griffiths D., Moore C.E., Welsh K.I., et al. MBL genotype and risk for invasive pneumococcal disease: a case-control study. Lancet 359 (2002) 1569-1573
52. Bergeron Y., Ouellet N., Deslauriers A.M., Simard M., Olivier M., and Bergeron M.G. Cytokine kinetics and other host factors in response to pneumococcal pulmonary infection in mice. Infect Immun 66 (1998) 912-922
53. Dallaire F., Oullet N., Bergeron Y., Turmel V., Gauthier M.C., Simard M., et al. Microbiological and inflammatory factors associated with the development of pneumococcal pneumonia. J Infect Dis 184 (2001) 292-300 [Erratum in: J Infect Dis 2001;184:392]
54. Marik P., Kraus P., Sribante J., Havlik I., Lipman J., and Johnson D.W. Hydrocortisone and tumor necrosis factor in severe community-acquired pneumonia. A randomized controlled study. Chest 104 (1993) 389-392
55. Moussa K., Michie H.J., Cree I.A., McCafferty A.C., Winter J.H., Dhillon D.P., et al. Phagocyte function and cytokine production in community acquired pneumonia. Thorax 49 (1994) 107-111
56. Gon Y., Hashimoto S., Hayashi S., Koura T., Matsumoto K., and Horie T. Lower serum concentrations of cytokines in elderly patients with pneumonia and the impaired production of cytokines by peripheral blood monocytes in the elderly. Clin Exp Immunol 106 (1996) 120-126
57. Kosmas E.N., Baxevanis C.N., Papamichail M., and Kordossis T. Daily variation in circulating cytokines and acute-phase proteins correlates with clinical and laboratory indices in community-acquired pneumonia. Eur J Clin Invest 27 (1997) 308-315
58. Bonten M.J., Froon A.H., Gaillard C.A., Greve J.W., de Leeuw P.W., Drent M., et al. The systemic inflammatory response in the development of ventilator-associated pneumonia. Am J Respir Crit Care Med 156 (1997) 1105-1113
59. Bruunsgaard H., Skinhøj P., Qvist J., and Pedersen B.K. Elderly humans show prolonged in vivo inflammatory activity during pneumococcal infections. J Infect Dis 180 (1999) 551-554
60. Montón C., Torres A., El-Ebiary M., Filella X., Xaubet A., and de la Bellacasa J.P. Cytokine expression in severe pneumonia: a bronchoalveolar lavage study. Crit Care Med 27 (1999) 1745-1753
61. Antunes G., Evans S.A., Lordan J.L., and Frew A.J. Systemic cytokine levels in community-acquired pneumonia and their association with disease severity. Eur Respir J 20 (2002) 990-995
62. Fernández-Serrano S., Dorca J., Coromines M., Carratalà J., Gudiol F., and Manresa F. Molecular inflammatory responses measured in blood of patients with severe community-acquired pneumonia. Clin Diagn Lab Immunol 10 (2003) 813-820
63. Maskin B., Fontán P.A., Spinedi E.G., Gammella D., and Badolati A. Evaluation of endotoxin release and cytokine production induced by antibiotics in patients with Gram-negative nosocomial pneumonia. Crit Care Med 30 (2002) 349-354
64. Millo J.L., Schultz M.J., Williams C., Weverling G.J., Ringrose T., Mackinlay C.I., et al. Compartmentalisation of cytokines and cytokine inhibitors in ventilator-associated pneumonia. Intensive Care Med 30 (2004) 68-74
65. Igonin A.A., Armstrong V.W., Shipkova M., Lazareva N.B., Kukes V.G., and Oellerich M. Circulating cytokines as markers of systemic inflammatory response in severe community-acquired pneumonia. Clin Biochem 37 (2004) 204-209
66. Kellum J.A., Kong L., Fink M.P., Weissfeld L.A., Yealy D.M., Pinsky M.R., et al. Understanding the inflammatory cytokine response in pneumonia and sepsis: results of the Genetic and Inflammatory Markers of Sepsis (GenIMS) Study. Arch Intern Med 167 (2007) 1655-1663
67. Calbo E., Alsina M., Rodríguez-Carballeira M., Lite J., and Garau J. Systemic expression of cytokine production in patients with severe pneumococcal pneumonia: effects of treatment with a β-lactam versus a fluoroquinolone. Antimicrob Agents Chemother 52 (2008) 2395-2402 [Erratum in: Antimicrob Agents Chemother 2008;52:3828]
68. Calbo E., Alsina M., Rodríguez-Carballeira M., Lite J., and Garau J. The impact of time on the systemic inflammatory response in pneumococcal pneumonia. Eur Respir J (2009) 10.1183/09031936.00052709 [Epub ahead of print]
69. Dehoux M.S., Boutten A., Ostinelli J., Seta N., Dombret M.C., Crestani B., et al. Compartmentalized cytokine production within the human lung in unilateral pneumonia. Am J Respir Crit Care Med 150 (1994) 710-716
70. Rijneveld A.W., Florquin S., Hartung T., Speelman P., and van der Poll T. Anti-tumor necrosis factor antibody impairs the therapeutic effect of ceftriaxone in murine pneumococcal pneumonia. J Infect Dis 188 (2003) 282-285
71. Cundell D., Masure H.R., and Tuomanen E.I. The molecular basis of pneumococcal infection: a hypothesis. Clin Infect Dis 21 Suppl. 3 (1995) S204-S211
72. Johnston Jr. R.B. Pathogenesis of pneumococcal pneumonia. Rev Infect Dis 13 Suppl. 6 (1991) S509-S517